SQSTM1 and cancer: Clinically, p62 overexpression has been identified as a potential prognostic marker in diverse cancers, such as leukemia [66], hepatocellular carcinoma [56], lung [86], pancreatic [87], ovarian [40], gastric [99], and colon cancers [48], and is often associated with poor outcomes.